|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 29, 2002; DOI 10.1182/blood-2001-11-0061.
IMMUNOBIOLOGY
From the Department of Immunology, and the Howard
Hughes Medical Institute, National Jewish Medical and Research
Center, and the Departments of Pediatrics, Medicine, Pharmacology, and
Biochemistry and Molecular Genetics, University of Colorado Health
Science Center, Denver; the Department of Cell Biology and Immunology,
Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands;
and the Department of Pathology, University of Geneva, Geneva,
Switzerland.
Autoimmune hemolytic anemia (AIHA) is a disease in which
autoantibodies against red blood cells (RBCs) lead to their premature destruction. Most clinically significant autoantibodies are of the
immunoglobulin G (IgG) type, which leads primarily to the uptake and destruction of RBCs by splenic and hepatic macrophages. Therapies such as corticosteroids and splenectomy are directed at
interfering with this process. Liposomally encapsulated clodronate (dichloromethylene diphosphonate) has previously been found to be a
potent antimacrophage agent. It selectively depletes animals of
macrophages within 24 hours of administration by inducing
apoptosis in these cells. Therefore, we hypothesized that
liposomal clodronate would be a useful agent for treating AIHA. We
tested this hypothesis in a mouse model of AIHA in which animals were
given either anti-RBC antibodies or preopsonized RBCs. In either case,
liposomal clodronate substantially decreased RBC destruction. This drug
formulation was effective within hours by first blocking and
then depleting phagocytic macrophages, and its action lasted for 1 to 2 weeks. Thus, in AIHA, liposomal clodronate therapy may act like a
temporary, medicinal splenectomy. As such, it may prove useful
in situations where rapid response to therapy is critical or other
medical therapies are inadequate.
(Blood. 2003;101:594-601) Autoimmune hemolytic anemia (AIHA) is an autoimmune
disease in which antibodies directed against the patient's own red
blood cells (RBCs) lead to their premature destruction.1
Anemia can be sudden and life threatening, or more gradual in onset.
Although most cases are idiopathic, association with other forms of
autoimmunity, malignancy, or infection is common.2-5 AIHA
occurs in both children and adults, with a wide age distribution.
AIHA can be mediated by immunoglobulin G (IgG), IgM, or,
rarely, IgA antibodies.1 Most clinically significant
cases, however, are caused by IgG antibodies.1,3 In these
patients, autoantibodies bind to RBCs and promote their uptake by
splenic and hepatic macrophages via Fc receptors.6
Although IgG antibodies can fix complement, the principal means of
destruction of RBCs in these cases is via phagocytosis.1,7-9 Therefore, even though B cells (often
with T-cell help) are producing the offending autoantibody, macrophages are the essential effector cells for the development of anemia. This
fact is reflected in the therapy for AIHA. Splenectomy and corticosteroids, mainstays of treatment, both ultimately interfere with
the phagocytosis of opsonized RBCs.1 Experimental therapy in animal models has also used the specific blocking of Fc-mediated uptake of RBCs by either genetic means or the use of anti-Fc
antibodies.10-14
Clodronate (dichloromethylene diphosphonate) is a bisphosphonate used
for treating osteolytic bone diseases and osteoporosis. Bisphosphonates
alleviate these disorders by inhibiting the function of osteoclasts.
There is evidence for both a direct blocking effect on these cells as
well as an apoptosis-inducing effect.15,16 Over a decade
ago, it was found that incorporation of this drug into liposomes
allowed it to become a potent antimacrophage agent both in vivo and in
vitro.17,18 The liposomal drug is taken up by macrophages
and rapidly causes apoptosis.19,20 Its effects in vivo are
influenced principally by its route of administration. Injection into
tissues leads to the depletion of macrophages from the tissue itself
and from draining lymph nodes. Intravenous injection of liposomally
encapsulated clodronate leads to nearly complete depletion of splenic
and hepatic macrophages as well as marginal zone dendritic cells within
24 hours.21 Unlike other methods of macrophage depletion,
however, this treatment does not lead to the secretion of
proinflamatory cytokines by the dying macrophages.22 Moreover, liposomal clodronate appears to have a very selective effect
on macrophages and phagocytic dendritic cells. Neutrophils and
lymphocytes have not been found to be directly affected by the
drug.21,23-24
Due to the well-established, critical role of macrophages in AIHA, we
wondered whether the potent and specific antimacrophage effects of
liposomal clodronate could be harnessed to treat this disease. To study
this question, we generated a model of AIHA in mice. In this model, we
treated mice with monoclonal anti-RBC antibodies derived from either
rats or autoimmune mice. These antibodies produced significant red
blood cell destruction and anemia, which we believe mimics spontaneous
AIHA. We found that liposomal clodronate was a very potent therapy to
prevent or alleviate anemia in this model.
Mice
Antibodies
Liposomes Clodronate (dichloromethylene diphosphonate) was provided by Roche Diagnostics (Mannheim, Germany). Clodronate liposomes were prepared as previously described.22 Briefly, 86 mg phosphatidylcholine (Lipoid EPC; LIPOID, Ludwigshafen, Germany) and 8 mg cholesterol (Sigma Chemical, St Louis, MO) were combined with 10 mL clodronate (0.7 M) solution and sonicated gently. The resulting liposomes were then washed to eliminate free drug. Empty liposomes were prepared under the same conditions with the use of phosphate-buffered saline (PBS) instead of the clodronate solution. All liposomes were passed through a 12-µm filter immediately prior to use in order to eliminate large lipid aggregates. Unless otherwise specified, 10 mL liposomes per kilogram of body weight (or 0.1 mL/10 g) were administered intravenously in all experiments. This dose has been previously shown to eliminate splenic and hepatic macrophages within 24 hours.17 PKH26 labeling of liposomes was performed by incubating the liposomal solution with an equal volume of diluent C (Sigma Chemical) containing 16 µM PKH26 (Sigma Chemical) for 5 minutes. Liposomes were then washed by centrifugation prior to injection.Flow cytometry/microscopy For flow cytometry of whole blood, animals were bled via a tail vein into EDTA saline. Circulating carboxyfluorescein succimidyl ester (CFSE)-labeled RBC numbers were determined via flow cytometry of whole blood. RBCs were defined by forward- versus side-scatter gating. Labeled cells were easily distinguished from unlabeled RBCs by CFSE fluorescence. Reticulocyte counts were determined by flow cytometry after staining with Auramine-O (Sigma Chemical). An absolute reticulocyte number was obtained by multiplying this percentage by the total number of RBCs per microliter. Quantification of RBC-bound antibody was determined by a flow cytometry-based method. RBCs were washed repeatedly in EDTA saline and then incubated with a cyanin 5 (Cy-5)-conjugated F(ab')2 goat anti-mouse/rat IgG reagent (Jackson Immunoresearch, West Grove, PA) and analyzed on a Facscaliber (Becton Dickinson, San Jose, CA).For examination of spleen or liver cells, tissues were dissected and treated with collagenase as follows: Organs were minced with sharp scissors and placed in a solution (2 mL) of collagenase D (100 U/mL) (Boehringer Mannheim, Mannheim, Germany) and DNAse (0.1 mg/mL) (Sigma Chemical) for 30 minutes at 37°C. Then, 1 mL of 0.1 M EDTA in PBS was added, and cells were incubated for another 5 minutes. The resulting cells and fragments were passed through a 100-µm strainer. RBCs were subsequently lysed with buffered ammonium chloride. After immunostaining, cells were either analyzed via flow cytometry or cytospun onto slides for microscopy. For flow cytometry, Oregon green-coupled anti-CD68 was used after permeabilizing cells with saponin. For microscopy, biotinylated primary antibodies against CD68 or F4/80 were used, followed by a streptavidin Cy-5 secondary reagent. Intracellular staining for RBCs was achieved in permeabilized cells by staining with trinitrophenyl (TNP)-coupled Ter-119, followed by a (hamster) anti-TNP antibody (BD Pharmingen, San Diego, CA), and then a Cy-3-coupled rabbit antihamster polyclonal antibody (Jackson Immunoresearch). Nuclei were counterstained with Hoechst 33342 (Molecular Probes). Preparation of RBCs RBCs were opsonized in vitro with Ter-119 by incubating 109 cells per milliliter with 2 µg/mL antibody for 30 minutes. This dose was determined empirically as a nonagglutinating dose that labeled all cells (data not shown). Cells were then washed to remove any unbound antibody. Dye labeling with CFSE (Molecular Probes) was performed as follows: 109 washed cells per milliliter were incubated with 50 µM CFSE in saline for 15 minutes at 37°C. They were then washed again prior to reinjection. For labeling of RBCs with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate (DiD) (Molecular Probes), cells were incubated at 109/mL in diluent C (Sigma Chemical) with 2 µM DiD for 5 minutes at room temperature. They were then reinjected into donor mice 2 or 3 times until approximately 60% of the donor mouse's RBCs were labeled with dye. This mouse was then bled to provide a source of labeled RBCs. This passage through a second donor mouse was performed because it led to a significant decrease in spontaneous dye uptake by splenocytes of untreated mice injected with nonopsonized RBCs.Determination of hemoglobin and RBC counts Blood hemoglobin concentrations were determined by a spectrophotometric method on a Sysmex NE1500 (Sysmex Corporation of America, Long Grove, IL). These values were correlated with RBC counts obtained on the same machine and on a Coulter Z1 (Miami, FL).
Liposomal clodronate alleviates acute IgG-induced anemia To induce anemia, C57BL/6 mice were injected with either Ter-119, an IgG2b monoclonal rat antimouse red blood cell antibody, or 1 of 2 different monoclonal autoantibodies derived from autoimmune NZB mice, 34-3C (IgG2a) or 4C8 (IgM). After a single injection of these antibodies, anemia progressed for approximately 48 to 72 hours in otherwise untreated mice (data not shown).As shown in Figure 1A, mice pretreated
with PBS-containing liposomes develop severe anemia, as documented by a
marked decrease in blood hemoglobin values, 36 hours after injection
with TER-119. This anemia was identical to antibody-challenged animals,
which received no pretreatment (data not shown). In contrast,
pretreatment with liposomal clodronate largely prevented the
development of this anemia. Injection of liposomal clodronate into
otherwise unperturbed mice had no significant effect on the blood
hemoglobin concentration, lymphocyte, neutrophil, or platelet counts
(Figure 1A and data not shown).
Liposomal clodronate also efficiently prevented the development of anemia after injection of a true autoantibody, 34-3C (Figure 1B). In contrast, injection of a monoclonal IgM, 4C8, produced an anemia that was not affected by liposomal clodronate. This finding is consistent with the fact that the 4C8 IgM anti-RBC autoantibody causes anemia in a "macrophage-independent" way, as a result of a massive agglutination of RBCs in liver and spleen.5 Liposomal clodronate was effective at preventing the development of anemia, despite high levels of RBC-bound IgG (Figure 1C). At the same time that animals were bled to assess anemia, an aliquot of blood was obtained to perform a flow cytometry-based Coombs assay. Representative assays from clodronate-treated mice, challenged with either TER-119 or 34-3C, are shown. The amount of RBC-bound antibody on circulating RBCs correlated with the dose of antibody administered and with the degree of anemia in animals not treated with clodronate (data not shown). Coombs assays performed on TER-119-treated animals were consistently higher than 34-3C-treated animals, despite a higher administered dose of 34-3C. This fact is consistent with the higher affinity of TER-119. Coombs assays performed on mice in the PBS liposome group revealed similar results (data not shown). Interestingly, however, the amount of RBC-bound antibody was moderately lower, consistent with the ongoing clearance of opsonized RBCs in these animals. Liposomal clodronate alleviates antibody-induced anemia when administered chronically To assess whether liposomal clodronate could be a useful reagent in a more chronic setting, the following experiment was performed. Increasing doses of 34-3C were administered to A/J mice over a 31-day period. The weekly antibody doses were as follows: week 1, 70 µg; week 2, 105 µg; week 3, 140 µg; week 4, 175 µg; and week 5, 105 µg (half-week only). The weekly dose was split into 2 intraperitoneal injections administered every 3 or 4 days. At the same time that antibody injections were started, weekly liposome treatments were begun. Mice were given injections of either PBS or clodronate liposomes once per week, for a total of 5 injections. At the end of a month, animals were bled to assess hemoglobin and reticulocyte counts (Figure 2). Because their IgG allotype matches that of 34-3C, A/J mice were chosen for this experiment in order to avoid the development of a neutralizing antiallotypic antibody response.
All animals developed anemia in this experiment, but liposomal clodronate-treated animals developed substantially less anemia. Furthermore, the difference in hemoglobin values of the 2 treatment groups could lead to an underestimate of the difference between them in RBC consumption, because there was a significant compensatory reticulocytosis. Animals in the PBS-treated group had 2- to 3-fold higher absolute reticulocyte counts (Figure 2B). Similarly to the experiments described in Figure 1, all circulating RBCs in mice from either treatment group were positive for surface-bound antibody (data not shown). Liposomal clodronate rapidly prevents the clearance of opsonized RBCs To further investigate how liposomal clodronate inhibited the development of anemia, we labeled RBCs with the fluorescent dye CFSE and opsonized them in vitro with anti-RBC antibody (Ter-119). These RBCs were then injected into mice that had been treated with either PBS or clodronate-containing liposomes 36 hours previously. Control mice received an identical number of dye-labeled, but not opsonized, RBCs. After 1 hour was allowed for the RBCs to equilibrate in the peripheral circulation, mice were bled at various time points. The RBCs that were opsonized in vitro with antibody were found to be rapidly cleared from the circulating pool (Figure 3A). Within 1 hour, more than 70% of these cells were removed from circulation. In contrast, mice pretreated with clodronate failed to clear any measurable number of antibody-coated RBCs from circulation for the length of the experiment (48 hours).
To determine how rapidly liposomal clodronate exerts its effects, we performed the following experiment: Mice were injected with identical numbers of dye-labeled, antibody-opsonized RBCs after receiving liposomal clodronate at various time points. They were bled 4 hours after the RBC injection. In our previous experiment, we had chosen to pretreat with clodronate 36 hours prior to injecting opsonized RBCs because this interval allowed for efficient depletion of splenic and hepatic macrophages before challenge. As is apparent from Figure 3B, liposomal clodronate very rapidly halts clearance of opsonized RBCs. It completely prevented clearance when given only 3 hours before the RBCs. Furthermore, even if given at the same time as opsonized RBCs (sequentially, in opposite retro-orbital injection sites), it was still able to prevent clearance of more than 60% of these cells. Together, these data (Figure 3A-B) indicate that liposomal clodronate causes a significant decrease in opsonized RBC clearance in less than 1 hour. Liposomal clodronate blocks phagocytosis by macrophages We expected that liposomal clodronate was able to prevent the clearance of opsonized RBCs in these experiments because it destroyed the macrophages that would normally take up antibody-coated RBCs. However, in our studies, the clodronate acted very quickly, within 1 hour, even though clodronate has not been reported to deplete macrophages from the spleen and liver of treated animals within this time frame.17-23 To investigate this issue further, we performed the following experiment.Mice were injected with either PBS or clodronate liposomes that had been labeled with the lipophilic dye PKH26. At 2 hours later, they were injected with RBCs that had been labeled with another dye, DiD. At 3 hours after the RBC injection, the animals were killed, and their liver and spleen cells were stained for CD68, a marker specific for mononuclear phagocytes (macrophages, dendritic cells, and monocytes). Most CD68+ cells in the spleen or liver, however, are macrophages because they are more abundant than either dendritic cells or monocytes in these tissues.26,27 As shown in Figure 4A, liposomal
clodronate does not significantly deplete macrophages
(CD68+ cells) from the spleen within 5 hours. Similar
results were seen in the liver (data not shown). This is in contrast to
later time points (24 hours), where liposomal clodronate very
thoroughly depletes spleen and liver macrophages17-23 (and
data not shown). Even though liposomal clodronate does not
deplete macrophages within the first few hours, it has a potent ability
to prevent the clearance of opsonized RBCs within this same time frame
(Figure 3). This apparent contradiction is explained in Figure 4B.
Both PBS and clodronate liposomes are taken up efficiently by CD68+ spleen and liver macrophages within 5 hours, as indicated by PKH fluorescence. Some macrophages have also taken up opsonized RBCs as indicated by DiD fluorescence. These double-positive cells are particularly evident in the mice that were treated with PBS liposomes. In contrast, far fewer macrophages from liposomal clodronate-treated mice have taken up RBCs. Furthermore, the cells in these mice, which have ingested RBCs, have a much lower MFI for DiD. This implies that they have each taken up fewer RBCs. These data indicate that the macrophages that have taken up liposomal clodronate are subsequently blocked from ingesting antibody-coated RBCs. This blocking effect, however, is observed only within a short window of time because within another 18 hours these macrophages will all be destroyed by the liposomal clodronate. The combined effects of initially blocking, then depleting, macrophages explains the rapid and complete onset of action for liposomal clodronate in our model. Engulfed RBCs are readily seen in the macrophages of untreated mice To confirm that what we were seeing by flow cytometry represented actual phagocytosis of RBCs and not some other process of dye acquisition, we performed microscopy on dispersed splenocytes. We examined dispersed cells because in the intact spleen, red pulp macrophages are in close contact with RBCs and it is very difficult to clearly determine whether any are intracellular.We injected antibody-opsonized RBCs into mice that either were
untreated or had received liposomal clodronate 24 hours previously. At
4 to 8 hours later, mice were killed; spleens were collagenase treated;
RBCs were lysed; and cells were fixed and permeabilized, stained with
the indicated antibodies, and cytospun onto slides for microscopy.
After RBC lysis, no free RBCs could be found on slides. As expected,
the only RBCs that were seen were those that appeared to be within
other cells. Few macrophages remained 24 hours after clodronate
treatment. Those that were found did not appear to have ingested RBCs
(data not shown). In control mice, however, macrophages were found to
have ingested RBCs by 3 different immunofluorescent stains. These
stains each reveal intact RBCs within macrophages. Figure
5A reveals an example of surface staining with F4/80, a macrophage-specific marker (in red), followed by intracellular staining with Ter-119 (anti-RBC, green; nuclei are counterstained blue). Figure 5B is an example of intracellular staining
with anti-CD68 (green) and Ter-119 (red). Finally, 5C is an example of
ingested CFSE-labeled RBCs' being visualized (in green) owing to CFSE
labeling prior to injection, along with intracellular staining for
CD68. CD68 can be seen colocalizing with the RBCs because it is
found largely in endosomes.
The effects of liposomal clodronate last 1 to 2 weeks A single dose of liposomal clodronate has previously been found to deplete splenic (red pulp) macrophages for 1 to 2 weeks in mice.21 After this time, natural turnover of red pulp macrophages leads to the replenishment of this population. This led us to wonder how long a single dose of liposomal clodronate would be effective in halting consumption of antibody-opsonized RBCs. To examine this, mice were injected with clodronate liposomes and then left undisturbed for 1 or 2 weeks. They were then injected with CFSE-labeled, antibody-opsonized RBCs. Mice were bled 4 hours later to assess survival of circulating RBCs. Control mice received either PBS or clodronate liposomes 36 hours before RBC injection. An additional control was the injection of an identical number of nonopsonized RBCs into an untreated mouse. As can be seen in Figure 6, treatment with clodronate 1 week prior to challenge with opsonized RBCs was as effective as treatment 36 hours before challenge. Treatment given 2 weeks prior to challenge was not as effective, however. These results are consistent with the persistent effects of liposomal clodronate on RBC uptake being due to macrophage depletion. As the red pulp macrophage population is replenished (in 1 to 2 weeks), the effects of liposomal clodronate on RBC clearance diminish.
Liposomal clodronate is effective over a wide range of doses The standard dose that we chose for treating animals in the experiments described so far in this paper was 10 mL per kilogram of body weight (or 0.1 mL/10 g). This dose was chosen because it has previously been shown to deplete splenic macrophages efficiently.22 This dose, however, may not be very practical for use in humans or large animals, because it represents a rather large infusion of liposomal drug, 700 mL for an average adult. Therefore, we wondered whether a smaller dose would be useful for preventing the uptake of opsonized RBCs.To examine this question, we injected mice with decreasing doses of
liposomal clodronate 36 hours prior to injection with opsonized,
dye-labeled RBCs. Control mice received either PBS liposomes (at 10 mL/kg) or an identical number of nonopsonized RBCs (and no liposomes).
Mice were bled 4 hours after injection to assess survival of
circulating RBCs. Figure 7 reveals that liposomal clodronate worked equivalently from 1 to 10 mL/kg and that
its efficacy dropped off below that dose. Although liposomal clodronate may not completely deplete splenic macrophages at these lower doses, it appears to be depleting (or blocking) the most actively
phagocytic ones at these doses. Therefore, it maintains its efficacy
over a wide range of doses.
Liposomal clodronate has previously been well characterized as a potent antimacrophage agent.17 For this reason, it has also been investigated as a potentially useful drug for treating autoimmune disorders such as adjuvant arthritis, uveitis, and experimental autoimmune encephalitis in animal models.28,29 More recently, it was found to be useful in a mouse model of immune thrombocytopenic purpura.24 This article demonstrates for the first time that it also appears to be a useful agent for treating antibody-induced anemia and, potentially, spontaneous AIHA. The experiments detailed in this paper show that liposomal clodronate consistently prevents or halts red blood cell destruction. It is effective when given prior to antibody challenge, as well as when given concurrently in a more chronic fashion. It protects against the development of anemia, despite the fact that virtually all circulating RBCs are antibody coated. Not surprisingly, liposomal clodronate failed to protect against IgM-mediated anemia. In addition to its striking potency, it has an extremely rapid onset of action. Furthermore, a single depleting dose is sufficient to protect mice from antibody-induced RBC destruction for 1 to 2 weeks. All of these characteristics are very desirable for a new agent to treat AIHA. Autoimmune hemolytic anemia is a highly variable disease. It can be caused by a variety of IgG and/or IgM antibodies. Numerous underlying conditions have been associated with it. Furthermore, its natural history is also quite variable. While many patients present with a slowly developing anemia, others, including the majority of patients in pediatric case series, present with sudden, severe anemia.30-32 We have attempted to model this disorder by administering a variety of anti-RBC antibodies in both a chronic and an acute fashion. We used a xenogeneic rat-derived antibody and a mouse-derived IgG monoclonal antibody with similar results. While this model does not mimic every aspect of the disease, we believe it is an appropriate one for studying antimacrophage agents in this disease. Current mainstays of therapy for AIHA include transfusion, corticosteroids, and, eventually, splenectomy.1 Each of these treatments has drawbacks. Transfusions have well-described risks that accompany their use in AIHA patients. Corticosteroids have a multitude of well-known acute and chronic side effects. They also have another shortcoming. The onset of action of corticosteroids is variable, frequently taking many hours (or even days).1 In patients presenting with very severe anemia, this shortcoming is a major source of concern and potential morbidity. In multiple case series, patients such as these, presenting with severe anemia (hemoglobin below 60 g/L [6 g/dL]), are quite common.30,32,33 Splenectomy, another mainstay of treatment, has several drawbacks as well. The most obvious one is routine surgical morbidity and mortality. Another drawback of splenectomy is its association with a life-long risk of fatal sepsis from encapsulated micro-organisms.34,35 Finally, splenectomy does not always alleviate AIHA, because hepatic macrophages may be responsible for a significant proportion of RBC consumption.36,37 In fact, the substantial role of hepatic Kupffer cells in the development of AIHA has been repeatedly shown in mice.6-9 The unpredictable efficacy of splenectomy is of particular concern in light of the short-term (surgical) and life-long (infectious) morbidities of this procedure. Liposomal clodronate, with its swift and potent ability to shut off RBC consumption, may reasonably be thought of as a temporary medicinal splenectomy. In our experimental system, it completely halted uptake of opsonized RBCs by the spleen, as a splenectomy would be expected to do. However, because the spleen is not removed, its function is eventually restored by the natural replenishment of macrophages. Liposomal clodronate offers many potential advantages over current therapy. Its speed of onset appears to be superior to that of corticosteroids. This may prove to be particularly useful in cases of severe, life-threatening anemia where cardiovascular compromise is evident. While liposomal clodronate is unlikely to replace corticosteroids, it may be useful as an adjunct therapy, allowing more rapid, reliable cessation of RBC destruction. Another potential advantage of clodronate is its ability to block or deplete phagocytic macrophages outside of the spleen. Macrophages in the liver and bone marrow, which are not accessible by surgical means, are affected as well.22 Liposomal clodronate may ultimately be useful as an intermittent therapy for patients who continue to experience significant anemia after splenectomy. Another important aspect of liposomal clodronate, which can be viewed as both an advantage and a disadvantage, is its temporary (1 to 2 weeks for a single dose) duration of action. While cases of AIHA in adult patients are typically chronic, most pediatric case series report that approximately half of all warm autoantibody (IgG-mediated) AIHA cases are acute, lasting less than 6 months.33,32 Accordingly, there may be situations in both adult and pediatric patients where temporary ablation of splenic function is desirable, but where life-long loss of splenic function is not necessary. If the use of liposomal clodronate improves medical management of AIHA, some patients may thereby avoid splenectomy and its life-long consequences. Our experimental data indicate that liposomal clodronate is effective when given repeatedly, and concurrently with anti-RBC antibody challenge. This "chronic" administration raises the possibility that liposomal clodronate could be administered repeatedly over a long period of time and thus supplant other medical (and surgical) therapies. Indeed, liposomal clodronate could conceivably be used intermittently as a steroid-sparing agent in chronic cases of AIHA. If administered only once every 1 to 2 weeks, it would be a very practical intravenous therapy to administer. Chronic use of liposomal clodronate remains speculative, however, because little is known (outside of the experiments detailed in this paper) about prolonged systemic depletion of macrophages with this agent. Indeed, questions regarding the safety of liposomal clodronate, particularly when administered chronically, have not yet been thoroughly addressed. Other investigators have found that liposomal clodronate has no apparent direct effects on cells other than mononuclear phagocytes.21 No alterations in circulating lymphocytes or neutrophils have been reported. Furthermore, in our experiments using dye-labeled liposomal clodronate, nearly all dye-containing cells within the spleen or liver were CD68+. This result implies that no cells other than mononuclear phagocytes received a significant dose of the drug. An important unanswered question, however, is how macrophage depletion with liposomal clodronate predisposes one to infection. This is a relevant question in light of the profound paralysis of macrophage function we observed in our model system. Other investigators have examined liposomal clodronate in a variety of short-term experimental models of infection. In some cases, it actually protects from mortality.38-42 In most, however, macrophage depletion worsens mortality or other infection-related end points.43-47 How this risk may compare with that of splenectomy has not yet been explored. This work describes the novel use of liposomal clodronate as a therapeutic agent in a murine model of autoimmune hemolytic anemia. Because of its promising efficacy, we believe that it warrants further investigation as a potential experimental therapy for AIHA.
The authors would like to thank the staff of the National Jewish Medical and Research Center clinical laboratory, particularly Rhonda Emerick and Sharon Lyons, for assistance with hemoglobin determinations.
Submitted November 27, 2001; accepted August 15, 2002.
Prepublished online as Blood First Edition Paper, August 29, 2002; DOI 10.1182/blood-2001-11-0061.
Supported by US Public Health Service grants CA-82086, AI-07365, AI-17134, AI-18785, and AI-22295; National Cancer Institute grant CA-46934 (supporting a core facility); the Melvin Garb Endowed Fellowship in Basic Immunology; and a grant from the Swiss National Foundation for Scientific Research.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Michael B. Jordan, NJC/HHMI -k512, 1400 Jackson St, Denver, CO 80206; e-mail: jordanm{at}njc.org.
1. Ware R, Rosse W. Autoimmune hemolytic anemia. In: Nathan DG,Orkin SH, eds. Nathan and Oski's Hematology of Infancy and Childhood. Vol 1. 5th ed. Philadelphia, PA: WB Saunders; 1998:499-522. 2. Schreiber AD. Systemic lupus erythematosus: hematological aspects. J Rheumatol. 1980;7:395-397[Medline] [Order article via Infotrieve].
3.
NIH conference: pathophysiology of immune hemolytic anemia.
Ann Intern Med.
1977;87:210-222 4. Axelson JA, LoBuglio AF. Immune hemolytic anemia. Med Clin North Am. 1980;64:597-606[Medline] [Order article via Infotrieve]. 5. Saif MW. HIV-associated autoimmune hemolytic anemia: an update. AIDS Patient Care STDS. 2001;15:217-224[CrossRef][Medline] [Order article via Infotrieve]. 6. Izui S, Berney T, Shibata T, Fulpius T, Fossati L, Merino R. Molecular and cellular basis for pathogenicity of autoantibodies. Tohoku J Exp Med. 1994;173:15-30[Medline] [Order article via Infotrieve].
7.
Fossati-Jimack L, Ioan-Facsinay A, Reininger L, et al.
Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.
J Exp Med.
2000;191:1293-1302
8.
Fossati-Jimack L, Reininger L, Chicheportiche Y, et al.
High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia.
J Exp Med.
1999;190:1689-1696
9.
Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, et al.
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.
J Exp Med.
2002;195:665-672 10. Hazenbos WL, Gessner JE, Hofhuis FM, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity. 1996;5:181-188[CrossRef][Medline] [Order article via Infotrieve].
11.
Hazenbos WL, Heijnen IA, Meyer D, et al.
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16).
J Immunol.
1998;161:3026-3032
12.
Meyer D, Schiller C, Westermann J, et al.
FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia.
Blood.
1998;92:3997-4002 13. Schiller C, Janssen-Graalfs I, Baumann U, et al. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol. 2000;30:481-490[CrossRef][Medline] [Order article via Infotrieve]. 14. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21-26[CrossRef][Medline] [Order article via Infotrieve]. 15. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998;38:375-388[CrossRef][Medline] [Order article via Infotrieve]. 16. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(suppl 2):S66-S80. 17. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate: an enzyme-histochemical study. Cell Tissue Res. 1984;238:355-358[Medline] [Order article via Infotrieve]. 18. Claassen I, Van Rooijen N, Claassen E. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage `suicide' technique. J Immunol Methods. 1990;134:153-161[CrossRef][Medline] [Order article via Infotrieve]. 19. van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods. 1996;193:93-99[CrossRef][Medline] [Order article via Infotrieve]. 20. Naito M, Nagai H, Kawano S, et al. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol. 1996;60:337-344[Abstract]. 21. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989;45:97-104[Abstract]. 22. van Rooijen N, Sanders A. Elimination, blocking, and activation of macrophages: three of a kind? J Leukoc Biol. 1997;62:702-709[Abstract]. 23. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93[CrossRef][Medline] [Order article via Infotrieve].
24.
Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, Isturiz MA.
Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model.
Blood.
2000;96:2834-2840 25. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109:280-287[CrossRef][Medline] [Order article via Infotrieve]. 26. Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice, IV: identification and distribution in mouse spleen. J Exp Med. 1975;141:804-820[Abstract].
27.
Steinman RM, Kaplan G, Witmer MD, Cohn ZA.
Identification of a novel cell type in peripheral lymphoid organs of mice, V: purification of spleen dendritic cells, new surface markers, and maintenance in vitro.
J Exp Med.
1979;149:1-16
28.
Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD.
Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages.
J Exp Med.
1990;172:1025-1033 29. Richards PJ, Williams BD, Williams AS. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology (Oxford). 2001;40:978-987. 30. Sokol RJ, Hewitt S, Stamps BK, Hitchen PA. Autoimmune haemolysis in childhood and adolescence. Acta Haematol. 1984;72:245-257[Medline] [Order article via Infotrieve]. 31. Carapella de Luca E, Casadei AM, di Piero G, Midulla M, Bisdomini C, Purpura M. Auto-immune haemolytic anaemia in childhood: follow-up in 29 cases. Vox Sang. 1979;36:13-20[Medline] [Order article via Infotrieve]. 32. Buchanan GR, Boxer LA, Nathan DG. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr. 1976;88:780-783[CrossRef][Medline] [Order article via Infotrieve]. 33. Heisel MA, Ortega JA. Factors influencing prognosis in childhood autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol. 1983;5:147-152[Medline] [Order article via Infotrieve]. 34. Bell WR Jr. Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37:22-25[Medline] [Order article via Infotrieve]. 35. Hansen K, Singer DB. Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. Pediatr Dev Pathol. 2001;4:105-121[CrossRef][Medline] [Order article via Infotrieve]. 36. Katkhouda N, Hurwitz MB, Rivera RT, et al. Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Ann Surg. 1998;228:568-578[CrossRef][Medline] [Order article via Infotrieve]. 37. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61:98-102[CrossRef][Medline] [Order article via Infotrieve].
38.
Kooguchi K, Hashimoto S, Kobayashi A, et al.
Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia.
Infect Immun.
1998;66:3164-3169
39.
Leemans JC, Juffermans NP, Florquin S, et al.
Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice.
J Immunol.
2001;166:4604-4611 40. Nieuwenhuijzen GA, Haskel Y, Lu Q, et al. Macrophage elimination increases bacterial translocation and gut-origin septicemia but attenuates symptoms and mortality rate in a model of systemic inflammation. Ann Surg. 1993;218:791-799[Medline] [Order article via Infotrieve]. 41. Savoy AC, Lupan DM, Manalo PB, et al. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun. 1997;65:1800-1807[Abstract]. 42. Wijburg OL, Simmons CP, van Rooijen N, Strugnell RA. Dual role for macrophages in vivo in pathogenesis and control of murine Salmonella enterica var. Typhimurium infections. Eur J Immunol. 2000;30:944-953[CrossRef][Medline] [Order article via Infotrieve]. 43. Ebe Y, Hasegawa G, Takatsuka H, et al. The role of Kupffer cells and regulation of neutrophil migration into the liver by macrophage inflammatory protein-2 in primary listeriosis in mice. Pathol Int. 1999;49:519-532[CrossRef][Medline] [Order article via Infotrieve].
44.
Emmanuilidis K, Weighardt H, Maier S, et al.
Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis.
J Immunol.
2001;167:3919-3927 45. Hamano S, Yoshida H, Takimoto H, et al. Role of macrophages in acute murine cytomegalovirus infection. Microbiol Immunol. 1998;42:607-616[Medline] [Order article via Infotrieve]. 46. Pinto AJ, Stewart D, van Rooijen N, Morahan PS. Selective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene diphosphonate: effects on antimicrobial resistance. J Leukoc Biol. 1991;49:579-586[Abstract]. 47. Qian Q, Jutila MA, Van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol. 1994;152:5000-5008[Abstract].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. A. Schirmer, S.-C. Song, J. P. Baliff, S. O. Harbers, R. A. Clynes, A. Krop-Watorek, G. R. Halverson, M. Czerwinski, and S. L. Spitalnik Mouse models of IgG- and IgM-mediated hemolysis Blood, April 1, 2007; 109(7): 3099 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Denny, P. Chandaroy, P. D. Killen, R. Caricchio, E. E. Lewis, B. C. Richardson, K.-D. Lee, J. Gavalchin, and M. J. Kaplan Accelerated Macrophage Apoptosis Induces Autoantibody Formation and Organ Damage in Systemic Lupus Erythematosus J. Immunol., February 15, 2006; 176(4): 2095 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. El-Azami-El-Idrissi, S. Franquin, M. J. Day, G. Mazza, C. J. Elson, V. Preat, C. J. Pfau, and J.-P. Coutelier Distinct Host-Dependent Pathogenic Mechanisms Leading to a Similar Clinical Anemia After Infection with Lymphocytic Choriomeningitis Virus Experimental Biology and Medicine, December 1, 2005; 230(11): 865 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Musaji, F. Cormont, G. Thirion, C. L. Cambiaso, and J.-P. Coutelier Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses Blood, October 1, 2004; 104(7): 2102 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jasinski, P. Pantazopoulos, R. P. Rother, N. van Rooijen, W.-C. Song, H. Molina, and M. Bessler A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins Blood, April 1, 2004; 103(7): 2827 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jiang, C. F. Reich III, and D. S. Pisetsky Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells Blood, September 15, 2003; 102(6): 2243 - 2250. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
